TY - JOUR
T1 - Clinical responses of large cell neuroendocrine carcinoma of the lung to cisplatin-based chemotherapy
AU - Yamazaki, Shigeo
AU - Sekine, Ikuo
AU - Matsuno, Yoshihiro
AU - Takei, Hidefumi
AU - Yamamoto, Noboru
AU - Kunitoh, Hideo
AU - Ohe, Yuichiro
AU - Tamura, Tomohide
AU - Kodama, Tetsuro
AU - Asamura, Hisao
AU - Tsuchiya, Ryosuke
AU - Saijo, Nagahiro
PY - 2005/8/1
Y1 - 2005/8/1
N2 - Background: The efficacy of chemotherapy in patients with large cell neuroendocrine carcinoma of the lung (LCNEC) remains unclear. Methods: Patients with LCNEC who received cisplatin-based chemotherapy were identified by reviewing 567 autopsied and 2790 surgically resected lung cancer patients. The clinical characteristics and objective responses to chemotherapy in these patients were analyzed. Results: Overall, 20 cases of LCNEC were identified, including stage IIIA (n = 3), stage IIIB (n = 6), stage IV (n = 6) and postoperative recurrence (n = 5) cases. Six patients had received prior chemotherapy, and 14 were chemo-naive patients. The patients had received a combination of cisplatin and etoposide (n = 9), cisplatin, vindesine and mitomycin (n = 6), cisplatin and vindesine (n = 4), or cisplatin alone (n = 1). One patient showed complete response and nine showed partial response, yielding an objective response rate of 50%. The response rate did not differ between patients with the initial diagnosis of SCLC and those with the initial diagnosis of NSCLC, however, the response rate in chemo-naive patients (64%) was significantly different from that in previously treated patients (17%). Conclusions: Our results suggest that the response rate of LCNEC to cisplatin-based chemotherapy was comparable to that of SCLC.
AB - Background: The efficacy of chemotherapy in patients with large cell neuroendocrine carcinoma of the lung (LCNEC) remains unclear. Methods: Patients with LCNEC who received cisplatin-based chemotherapy were identified by reviewing 567 autopsied and 2790 surgically resected lung cancer patients. The clinical characteristics and objective responses to chemotherapy in these patients were analyzed. Results: Overall, 20 cases of LCNEC were identified, including stage IIIA (n = 3), stage IIIB (n = 6), stage IV (n = 6) and postoperative recurrence (n = 5) cases. Six patients had received prior chemotherapy, and 14 were chemo-naive patients. The patients had received a combination of cisplatin and etoposide (n = 9), cisplatin, vindesine and mitomycin (n = 6), cisplatin and vindesine (n = 4), or cisplatin alone (n = 1). One patient showed complete response and nine showed partial response, yielding an objective response rate of 50%. The response rate did not differ between patients with the initial diagnosis of SCLC and those with the initial diagnosis of NSCLC, however, the response rate in chemo-naive patients (64%) was significantly different from that in previously treated patients (17%). Conclusions: Our results suggest that the response rate of LCNEC to cisplatin-based chemotherapy was comparable to that of SCLC.
KW - Chemotherapy
KW - Cisplatin
KW - Lung cancer
KW - Neuroendocrine carcinoma
UR - http://www.scopus.com/inward/record.url?scp=22044450203&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=22044450203&partnerID=8YFLogxK
U2 - 10.1016/j.lungcan.2005.01.008
DO - 10.1016/j.lungcan.2005.01.008
M3 - Article
C2 - 16022916
AN - SCOPUS:22044450203
VL - 49
SP - 217
EP - 223
JO - Lung Cancer
JF - Lung Cancer
SN - 0169-5002
IS - 2
ER -